Panelists provide their key considerations when determining appropriate treatment options for patients with major depressive disorder.
Video Series
Advertisement
Key opinion leaders discuss the importance of early effective treatment for patients with MDD.
Advertisement
Dr Siefker-Radtke provides her closing thoughts on her takeaways from ESMO 2022, including a study focusing on penpulimab plus anlotinib.
Disitamab vedotin is a promising antibody-drug conjugate option undergoing evaluation for patients with metastatic urothelial cancer.
Dr Siefker-Radtke shares takeaways from the SOGUG-AUREA study and its influence on treatment for patients with urothelial cancer.
Unmet needs in MDS treatment management are proposed by Salman Fazal, MD.
Advertisement
Dr Haumschild leads a discussion regarding cost-associated burden for patients with MDS.
Major depressive disorder treatment failure can lead to subsequent costs and poor outcomes, affecting payer considerations in the treatment landscape.
Consequences attributed to poorly controlled and recurrent MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.
The SOGUG-AUREA study explored overall survival of atezolizumab plus split-dose cisplatin-gemcitabine in patients with locally advanced and metastatic urothelial cancer.
Advertisement
Enfortumab vedotin monotherapy or its combination with pembrolizumab could significantly evolve the treatment landscape for urothelial cancer.
Drs Fazal and Zeidan illustrate the roles and challenges of implementing oral therapies in MDS treatment management.
Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.
Expert panelists discuss the lack of diversity among available treatment options for MDD.
Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP, open a discussion surrounding payer considerations relating to the treatment of major depressive disorder (MDD).
Dr Siefker-Radtke explores unmet needs in the treatment of patients with urothelial cancer and how novel immunotherapies can address some of the challenges with traditional chemotherapy.
Key considerations for appropriate MDS treatment selection are discussed by expert panelists.
Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.
Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.
Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).
Syma Iqbal, MD, shares final insights into the ESCC and GI cancer treatment landscape, emphasizing the utilization of key diagnostic tools and innovative treatment strategies.
Experts discuss the impact of supportive care in the MDS treatment landscape.
Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.
Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.
Syma Iqbal, MD, discusses how ESCC and GI cancer treatment pathways may have a myriad of effects on patient quality of life.
A medical expert discusses treating patients with ESCC and GI cancers as recommended by current FDA and NCCN guidelines.
Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.
Expert panelists explore challenges impacting care access for patients with MDS.
In her final thoughts, Dr Oskouei discusses how patient care may be improved by increased access to biosimilars.
The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.
